Results 181 to 190 of about 57,312 (301)

Age‐Associated Targetable Genomic Alterations and PD‐L1 Expression in 2509 Patients With Pulmonary Ground‐Glass Opacities

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Aim To investigate the landscape of targetable genomic alterations and programmed cell death ligand 1 (PD‐L1) expression in pulmonary ground‐glass opacities (GGOs) and their association with age. Methods A total of 2509 patients with GGOs were retrospectively analyzed.
Wen‐Fang Tang, Si‐Qi Huang, Yi‐Duo Lin, Hong‐Ji Li, Qing‐Hua Huang, Jing Chen, Zhen‐Bin Qiu, Wei‐Zhao Huang, Ying‐Meng Wu, Hong‐Yu Ye, Wei Xu, Xue‐Ning Yang, Yi‐Long Wu, Hai‐Ming Jiang, Yi Liang, Xuan Tang, Wen‐Zhao Zhong   +16 more
wiley   +1 more source

Three in one: a case report of mixed neuroendocrine tumor, goblet cell adenocarcinoma and low-grade mucinous neoplasm in a single appendix. [PDF]

J Surg Case Rep
Lin V, Rutland T, Gibson K, Farzin M.
europepmc   +1 more source

Hiding in plain sight: DICER1‐associated yolk sac tumour masquerading as an endometrioid carcinoma of the ovary

Histopathology, EarlyView.
Lili Fu, Afrida Ahmed, Celine Domecq, Elizabeth N Skinner, William D Foulkes   +4 more
wiley   +1 more source

Multi‐Transcriptomic Analysis Reveals That EREG‐Driven TME Crosstalk Defines Anti‐EGFR Response in Colorectal Cancer

Cancer Medicine, Volume 15, Issue 5, May 2026.
A multi‐transcriptomic analysis reveals the “EREG/EGFR/CSF axis” as a key intercellular network in the tumor microenvironment that dictates anti‐EGFR sensitivity in colorectal cancer. ABSTRACT Sidedness influences colorectal cancer (CRC) prognosis and treatment response, yet the mechanism dictating differential EGFR inhibitor (EGFRI) sensitivity is ...
Atsuki Taniguchi, Shunsuke Kagawa, Shohei Nogi, Tomohiko Yagi, Nobuhiko Kanaya, Shinji Kuroda, Satoru Kikuchi, Yoshihiko Kakiuchi, Hiroshi Tazawa, Toshiyoshi Fujiwara   +9 more
wiley   +1 more source

Painless perianal mucinous adenocarcinoma: A case report and literature review. [PDF]

Oncol Lett
Shi J, Wang X, Yang J, Li G, Zhang Y.
europepmc   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Mucinous adenocarcinoma with peritoneal carcinomatosis presenting as acute abdomen: a case report. [PDF]

Front Oncol
Nusretoğlu R, Ali AK.
europepmc   +1 more source

Anal Mucinous Adenocarcinoma [PDF]

, 2020
openaire   +1 more source

Beyond the stomach: early bone metastases revealing canine gastric adenocarcinoma

Journal of Small Animal Practice, EarlyView.
G. d. S. Schiavi, C. Y. A. Kawabata, J. V. P. Campos, L. N. Lima, A. M. A. Abranches, L. L. Patente, V. D. Laranjeira, V. Nowosh, J. V. de Assis, A. J. S. de Souza   +9 more
wiley   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source